Research Article
Volume 12 Issue 3 - 2020
Non Motor Symptoms and their Impact on Quality of Life in Moroccan Patients with Parkinson Disease
Hajar Elyachkouri1*, Najib Kissani1, Mohammed Khaled Choulli2 and Mohammed Chraa1
1Neurology Department, Mohammed VI University Hospital, Kadi Ayad Medical School University, Marrakesh, Morocco
2Physiology Department, Kadi Ayad University, Marrakesh, Morocco
*Corresponding Author:Hajar Elyachkouri, Neurology Department, Mohammed VI University Hospital, Kadi Ayad Medical School University, Marrakesh, Morocco.
Received: January 24, 2020; Published:February 17, 2020




Abstract

Patients with Parkinson disease are more impaired by Non-motor symptoms (NMS) than motor symptoms, especially in advanced stages. Unfortunately, in most cases, it is unrecognized. NMS are important determinant of disability and quality of life in patients with Parkinson disease (PD). This is a prospective observational study conducted in the neurology department of Mohammed VI university hospital, on NMS in Moroccan patients with Parkinson disease. We report 115 patients (Males 61.5% mean age 59.1years) diagnosed over a period of 18 months. Patients were administered detailed questionnaires by a neurologist. The mean age of onset was 53.71 (ranged from 23 to 76 years). Pain (60.3%), constipation (59%), urinary urgency (52.6%), sleep disturbances mainly insomnia (57.7), and depression (47.4%), were the most frequent NMS in our cohort, while hallucinations (29.5%), diplopia (12.8%) and memory impairment (30.8%) were less frequent.

There was a difference between males and females on the distribution of NMS, depressed mood, anxiety and sleep problems were more common in females, while urinary disorders, constipation, sexual dysfunction were more common in males. NMS are positively correlated to the H&Y stage and to duration of the disease.

We used the Parkinson’s disease quality of life questionnaire Summary Index score (PDQ39IS) to assess the impact on quality of life in patients. Our results showed that the impact affected mainly the emotional well-being (47, 81%). Mobility was affected in second place (44.13%), followed by daily activities (42, 9%).

Keywords: Parkinson Disease; Non-Motor Symptoms; Quality of Life; NMSS; PDQ3; Moroccan Cohort

References

  1. De Souza Aaron., et al. “Non motor symptoms in indian patients with parkinson’s disease”. Basal Ganglia 5.4 (2015): 89-93.
  2. Pfeiffer RF. “Non-motor symptoms in Parkinson’s disease”. Parkinsonism ad Related Disorders 22 (2016): S119-S122. 
  3. Wei Song., et al. “The impact of non motor symptoms on the health-related quality of life of parkinson’s disease patients from southwest China”. Parkinsonism and Related Disorders 20 (2014): 149-152.
  4. Chaudhuri K Ray and Antony Schapira. “Non motor symptoms of Parkinson disease: Dopaminergic pathophysiology and treatment”. Lancet Neurology 8.5 (2009): 464-74.
  5. Martinez Martin., et al. “The impact of non motor symptoms on health related quality of life of patients with parkinson disease”. Movement Disorders 26 (2011): 399-406.
  6. Huijuan Li., et al. “Non motor symptoms are independently associated with impaired health-related quality of life in chineese patients with Parkinson disease”. Movement Disorders 25 (2010): 2740-2746.
  7. Santos-Garcia Diego and Raùl de la fuente-Fernandez. “Impact of non motor symptoms on health-related and perceived quality of life in Parkinson disease”. Journal of the Neurological Sciences 332 (2013): 136-140.
  8. Tysnes Ole-Bjørn and Anette Storstein. “Epidemiology of parkinson’s disease”. Journal of Neural Transmission 124.8 (2017): 901-905.
  9. Braak Heiko., et al. “Stages in the development of Parkinson's disease related pathology”. Cell and Tissue Research 318.1 (2004): 121-134.
  10. De Rijk MC., et al. “Prevalence of Parkinson’s disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group”. Neurology 54.5 (2000): S21-3.
  11. De Lau LM and MM Breteler. “Epidemiology of Parkinson’s disease”. Lancet Neurology 5.6 (2006): 525-535.
  12. Van Den Eeden SK., et al. “Incidence of Parkinson’s disease: variation by age, gender and race/ethnicity”. American Journal of Epidemiology 157.11 (2003): 1015-1022.
  13. Cosentino Carlos., et al. “Frequency of non-motor symptoms in Peruvian patients with Parkinson’s disease”. Arquivos de Neuro-Psiquiatria 71.4 (2013): 216-219.
  14. Solla Paolo., et al. “Gender differences in motor and non-motor symptoms among Sardinian patients with Parkinson's disease”. Journal of the Neurological Sciences 323 (2012): 33-39.
  15. Gillies GE and S McArthur. “Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines”. Pharmacological Reviews 62.2 (2010): 155-98.
  16. Becker JB. “Gender differences in dopaminergic function in striatum and nucleus accumbens”. Pharmacology Biochemistry and Behavior 64.4 (1999): 803-812. 
  17. Veliskova J and SL Moshe. “Sexual dimorphism and developmental regulation of substantia nigra function”. Annals of Neurology 50.5 (2001): 596-601. 
  18. Walker QD., et al. “Dopamine release and uptake are greater in female than male rat striatum as measured by fast cyclic voltammetry”. Neuroscience 95.4 (2000): 1061-1070. 
  19. Green PS and JW Simpkins. “Neuroprotective effects of estrogens: potential mechanisms of action”. International Journal of Developmental Neuroscience 18.4-5 (2000): 347-358. 
  20. Miller DB., et al. “The impact of gender and estrogen on striatal dopaminergic neurotoxicity”. Annals of the New York Academy of Sciences 844 (1998): 153-65.  
  21. Sawada H and S Shimohama. “Neuroprotective effects of estradiol in mesencephalic dopaminergic neurons”. Neuroscience and Biobehavioural Reviews 24.1 (2000): 143-147.
  22. Chaudhuri K Ray., et al. “International multicenter pilot study of the first comprehensive self-completed non motor symptoms questionnaire for Parkinson disease: the non motor symptoms questionnaire study”. Movement Disorders 21 (2006): 916-23.
  23. Martinez Martin P., et al. “International study on the psychometric attributes of the non motor symptoms scale in Parkinson disease”. Neurology 73 (2009): 1584-1591.
  24. Martinez-Martin P., et al. “Prevalence of non motor symptoms in Parkinson diseases in an international setting: Study using non motor symptoms questionnaire in 545 patients”. Movement Disorders 22 (2007): 1623-1629. 
  25. Barone P., et al. “The PRIAMO study: A multicenter assessment of non motor symptoms and their impact on quality of life in Parkinson disease”. Movement Disorders 24 (2009): 1641-1649. 
  26. Krishnan S., et al. “Do non motor symptoms in Parkinson’s disease differ from normal aging”. Movement Disorders 26.11 (2011): 2110-2113.
  27. Cheon SM., et al. “Non-motor off symptoms in Parkinson’s disease”. Journal of Korean Medical Science 24.2 (2009): 311-314.
  28. Yong MH., et al. “Differentiating non-motor symptoms in Parkinson’s disease from controls and hemifacial spasm”. PLoS One 8.2 (2013): e49596.
  29. Crosiers D., et al. “Non-motor symptoms in a Flanders-Belgian population of 215 Parkinson’s disease patients as assessed by the Non-Motor Symptoms Questionnaire”. American Journal of Neurodegenerative Disease 1.2 (2012): 160-167.
  30. Tibar H., et al. “Non-Motor Symptoms of Parkinson’s Disease and Their Impact on Quality of Life in a Cohort of Moroccan Patients”. Frontiers in Neurology 9 (2018): 170.
  31. Khedr EM., et al. “Prevalence of non motor features in a cohort of Parkinson’s disease patients”. Clinical Neurology and Neurosurgery 115 (2013): 673-677.
  32. Yu B., et al. “Study of an integrated non-motor symptoms questionnaire for Parkinson’s disease”. Chinese Medical Journal 123.11 (2010): 436-1440. 
  33. Maeda T., et al. “Clinical manifestations of non motor symptoms in 1021 Japanese Parkinson disease patients from 35 medical centers”. Parkinsonism and Related Disorders 38 (2017): 54-60.
  34. Spica V., et al. “Prevalence of non-motor symptoms in young-onset versus late-onset Parkinson’s disease”. Journal of Neurology 260.1 (2013): 131-137.
  35. Breen KC and G Drutyte. “Non-motor symptoms of Parkinson’s disease: the patient’s perspective”. Journal of Neural Transmission 120 (2013): 531-535.
  36. Baba Y., et al. “Gender and the Parkinson's disease phenotype”. Journal of Neural Transmission 252.10 (2005): 1201-1205.
  37. Martinez-Martin P., et al. “Gender-related differences in the burden of non-motor symptoms in Parkinson's disease”. Journal of Neural Transmission 259.8 (2012): 1639-1647.
  38. Zappia M., et al. “Body weight influences pharmacokinetics of levodopa in Parkinson's disease”. Clinical Neuropharmacology 25 (2002): 79-82. 
  39. Haaxma CA., et al. “Gender differences in Parkinson's disease”. Journal of Neurology, Neurosurgery, and Psychiatry 78.8 (2007): 819-824.
  40. Antonini A., et al. “The progression of non-motor symptoms in Parkinson’s disease and their contribution to motor disability and quality of life”. Journal of Neurology 259 (2012): 2621-2631.
  41. Juri C., et al. “Features associated with the development of nonmotor manifestations in Parkinson’s disease”. Arquivos de Neuro-Psiquiatria 66.1 (2008): 22-25.
  42. Guo X., et al. “Disease duration-related differences in non-motor symptoms: a study of 616 Chinese Parkinson’s disease patients”. Journal of the Neurological Sciences 330 (2013): 32-37.
  43. Rana AQ., et al. “Prevalence and relation of dementia to various factors in Parkinson’s disease”. Psychiatry and Clinical Neurosciences 66.1 (2012): 64-68.
  44. Schaeffer E and Berg D. “Dopaminergic Therapies for Non-motor Symptoms in Parkinson’s Disease”. CNS Drugs 31.7 (2017): 551-570. 
  45. Bastide MF., et al. “Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson’s disease”. Progress in Neurobiology 132 (2015): 96-168. 
  46. Hinnell C., et al. “Nonmotor versus motor symptoms: how much do they matter to health status in Parkinson's disease”. Movement Disorders 27 (2012): 236-241. 
  47. Leonardi M., et al. “Relationships between disability, quality of life and prevalence of nonmotor symptoms in Parkinson's disease”. Parkinsonism and Related Disorders 18 (2012): (35-39).
  48. Ou R., et al. “Clinical characteristics and quality of life in Chinese patients with Parkinson’s disease beyond 20 years”. Neurological Research 40.4 (2018): 312-317. 
  49. Ton LCS., et al. “Validity and reliability of the PDQ-39 and the PDQ-8 in English-speaking Parkinson disease patients in Singapore”. Parkinsonism and Related Disorders 10 (2004): 493-499.
  50. Jenkinson C., et al. “The Parkinson disease questionnaire (PDQ-39): Evidence for a method of imputing missing data”. Age Ageing 35 (2006): 497-502.
Citation: Hajar Elyachkouri.., et al. “Non Motor Symptoms and their Impact on Quality of Life in Moroccan Patients with Parkinson Disease”. EC Neurology 12.3 (2020): 01-10.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


August Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the August issue of respective journals and can be viewed in the current issue pages.

Submission Deadline for September Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the September issue of respective journals. Submissions are accepted on/before August 15, 2020.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to editor@ecronicon.uk